Genmab A/SGMABNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P29
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2025-3.36%
20248.28%
202394.83%
202281.93%
2021-67.74%
2020404.20%
2019126.08%
2018-64.18%
2017409.30%
201667.33%